Try our Advanced Search for more refined results
Life Sciences
-
January 22, 2026
Medical Cannabis Co. Says Data Breach Didn't Lead To Injury
An Ohio medical cannabis company has said a consolidated class action in federal court should be dismissed as it doesn't allege any of the plaintiffs' data was accessed in a data breach or that the breach could be linked to any real damage.
-
January 22, 2026
Investors Drop LA Law Firm From Bioscience Fraud Suit
A group of investors including a "Toy Story" screenwriter pursuing an $87 million fraud suit against a bioscience company in California state court has agreed to drop claims against a California law firm and its name partner, with the firm in turn withdrawing an anti-SLAPP motion it filed in the suit.
-
January 21, 2026
Holmes Seeks Trump Clemency For Theranos Fraud Sentence
Former Theranos CEO Elizabeth Holmes has asked President Donald Trump to commute an 11-year prison sentence she's been serving for defrauding investors with bogus blood-testing technology, according to the U.S. Department of Justice's Office of the Pardon Attorney.
-
January 21, 2026
CVS, UnitedHealth, Express Scripts Duck PBM Antitrust Suit
A Missouri federal judge has thrown out a proposed class action accusing the country's three largest pharmacy benefit managers — owned by CVS, UnitedHealth Group and Cigna Group — of inflating prescription costs through their rebating practices.
-
January 21, 2026
Bristol-Myers' Worker Arbitration Push Scrutinized On Appeal
A Washington Court of Appeals panel expressed reluctance to award Bristol-Myers Squibb Co.'s bid to send a former worker's age discrimination case to arbitration Wednesday, while also casting some doubt on the ex-employee's stance that the arbitration pact she signed was invalid.
-
January 21, 2026
Medtronic 'Blocked' Surgical Device Competition, Jury Told
An executive at Applied Medical Resources Corp. on Tuesday told a California federal jury considering antitrust claims against Medtronic Inc. that a surgical device his company introduced a decade ago had great success in Europe but was "blocked" in the U.S. by Medtronic's practice of "bundling" products.
-
January 21, 2026
Texas AG Launches Investigation Into Vaccine Incentives
The Texas attorney general launched what it characterized as a sweeping, multi-industry investigation into financial incentives for medical providers to recommend childhood vaccines, saying providers regularly dish out vaccines that "are not proven to be safe or necessary."
-
January 21, 2026
Novartis Gets Win On Entresto Patent Tied To Earlier Ruling
A Delaware federal judge found Wednesday that MSN Pharmaceuticals Inc. infringed a patent covering Novartis Pharmaceuticals Corp.'s blockbuster cardiovascular drug Entresto, saying the issue has already been litigated before.
-
January 21, 2026
Allergan Says Fed. Circ.'s Ax Of $39M Win Misread Record
A Federal Circuit decision reversing a $39 million verdict against Sandoz in Allergan's suit accusing it of infringing an eyelash growth drug patent misunderstood the evidence and was based on an "indisputably false" premise, Allergan said in a petition for rehearing Tuesday.
-
January 21, 2026
Teva's Inconsistent Args In IUD Trial 'Troubling,' Judge Says
Teva Pharmaceuticals quickly ran afoul of a Georgia federal judge Wednesday in its first trial over alleged defects in its Paragard IUD, as the court chastised the drugmaker's attorneys over "very troubling" inconsistencies in their opening statements to jurors.
-
January 21, 2026
FTC Mulling Deal With Express Scripts In PBM Case
The Federal Trade Commission is considering a potential settlement with Express Scripts in the agency's case accusing the country's three largest pharmacy benefit managers of inflating insulin prices through rebate schemes.
-
January 21, 2026
Fla. Dispensary Exposed Patient Data Via Google, Suit Says
A Florida man is suing a dispensary website in federal court, alleging it has violated federal health confidentiality laws by using Google Analytics Pixel on its website, which he said intercepts and collects private information for use in advertising.
-
January 20, 2026
Justices To Clarify What's Fair Game With 'Skinny Labels'
A new U.S. Supreme Court patent case that will require the justices to spell out what generic-drug makers can say when marketing drugs with so-called skinny labels will shape whether and how those companies use the tactic of carving out patented uses from labels, attorneys say.
-
January 20, 2026
Orrick Expands IP Team With Cadwalader, Kirkland Litigators
Orrick Herrington & Sutcliffe LLP has beefed up its intellectual property litigation team with three new partners experienced in counseling technology and life sciences clients, adding two former Cadwalader Wickersham & Taft LLP litigators in New York and a former Kirkland & Ellis LLP partner in Los Angeles.
-
January 20, 2026
Dentsply Can't Shed Investors' Aligner Injury Cover-Up Suit
Dental supply company Dentsply Sirona Inc. must face a proposed investor class action alleging it covered up medical injuries and other issues affecting an aligner business it acquired for $1 billion, and caused shareholder losses when the injuries were revealed and the acquisition collapsed.
-
January 20, 2026
Law360 Names Firms Of The Year
Eight law firms have earned spots as Law360's Firms of the Year, with 48 Practice Group of the Year awards among them, achieving milestones such as high-profile litigation wins at the U.S. Supreme Court and 11-figure merger deals.
-
January 20, 2026
Fed. Circ. Revives Inventor's Spinal Patent Case Against DePuy
The Federal Circuit on Tuesday revived an inventor's patent infringement suit against DePuy Synthes Cos., ruling that the persuasiveness of expert testimony that was excluded by a lower court is best left for the jury.
-
January 20, 2026
Philips CPAP Cancer Suit Sent Back To Kentucky
A Pennsylvania federal judge has sent back to state court a suit in the multidistrict litigation over recalled CPAP devices brought against Philips RS North America by a Kentucky woman who claims her sleep apnea machine caused her cancer, finding that a middleman supplier wasn't added to thwart federal jurisdiction.
-
January 20, 2026
NY Judge Orders SD To Pause Action Against Abortion Ads
A New York federal judge has temporarily barred South Dakota officials from taking action against an abortion rights group that launched an advertising campaign in the state promoting its website, which explains how to order abortion medication online.
-
January 20, 2026
Ex-Med Spa Workers Say Poaching Claims Can't Stay In Conn.
Two former Connecticut medical spa workers have asked a judge to dismiss claims they lured clients and a colleague to a nearby competitor, saying their employment agreements select Delaware as the necessary forum and venue for any dispute.
-
January 20, 2026
Johnson & Johnson Faces 2nd Talc Trial In Philadelphia
Counsel for a woman who died of ovarian cancer told a Philadelphia jury Tuesday that her condition was caused by her decades-long use of asbestos-laced talc in Johnson & Johnson's flagship baby powder and that the company kept pushing the product in the market despite knowing about its health risks.
-
January 20, 2026
Va. Lawmakers Eye Psilocybin Regulation Pending FDA Action
Virginia lawmakers have introduced legislation directing state regulators to develop rules governing the prescription, possession and use of medical psilocybin, the active compound in psychoactive mushrooms, in the event that it receives approval from the U.S. Food and Drug Administration.
-
January 20, 2026
CorMedix Investors Seek First OK Of Governance Reform Deal
Investors in CorMedix Inc. have told a New Jersey federal judge that company directors have agreed to implement several corporate governance reforms to resolve a consolidated shareholder derivative lawsuit accusing the executives of making misleading statements about delays in the regulatory approval of the company's lead drug candidate.
-
January 20, 2026
McCarter & English Knocks Down Biotech Malpractice Appeal
A New Jersey appellate court on Tuesday upheld the dismissal of a biotech company's malpractice and related claims against McCarter & English LLP, finding the biotech company was required to bring those allegations during the firm's earlier suit to recover more than $837,000 in unpaid legal fees.
-
January 20, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court wrapped up last week with a mix of deal litigation, governance fights and disclosure battles, including a proposed settlement over a contested medical device sale, a merits dismissal tied to a $2 billion biotech exit and dueling lawsuits over Paramount Skydance's pursuit of Warner Bros. Discovery.
Expert Analysis
-
Opinion
DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable
In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.
-
Del. Ruling Reaffirms High Bar To Plead Minority Control
The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray.
-
Series
Law School's Missed Lessons: Client Service
Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.
-
How Occasional Activists Have Reshaped Proxy Fights
The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.
-
What To Expect After FDA Warnings To GLP-1 Compounders
The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.
-
Where 4th And 9th Circ. Diverge On Trade Secret Timing
Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.
-
Series
Adapting To Private Practice: 3 Tips On Finding The Right Job
After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.
-
Series
Painting Makes Me A Better Lawyer
Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.
-
Courts Are Still Grappling With McDonnell, 9 Years Later
The Seventh and D.C. Circuits’ recent decisions in U.S. v. Weiss and U.S. v. Paitsel, respectively, demonstrate that courts are still struggling to apply the U.S. Supreme Court’s 2016 ruling in McDonnell v. U.S., which narrowed the scope of “official acts” in federal bribery cases, say attorneys at Quinn Emanuel.
-
AI Will Transform Patent Examination For The Better
The U.S. Patent and Trademark Office's increasing use of artificial intelligence tools will result in patents that are more thoroughly vetted, and patent applicants and practitioners will need to adapt their drafting strategies and address stronger and more sophisticated rejections, say attorneys at Troutman.
-
Hybrid Claims In Antitrust Disputes Spark Coverage Battles
Antitrust litigation increasingly includes claims for breach of warranty, product liability or state consumer protection violations, complicating insurers' reliance on exclusions as courts analyze whether these are antitrust claims in disguise, says Jameson Pasek at Caldwell Law.
-
Drug Ad Crackdown Demonstrates Admin's Aggressive Stance
Recent actions by the U.S. Food and Drug Administration and U.S. Department of Health and Human Services targeting pharmaceutical companies' allegedly deceptive advertising practices signal an active — potentially even punitive — intent to regulate direct-to-consumer advertising out of existence, say attorneys at King & Spalding.
-
Protecting Sensitive Court Filings After Recent Cyber Breach
In the wake of a recent cyberattack on federal courts' Case Management/Electronic Case Files system, civil litigants should consider seeking enhanced protections for sensitive materials filed under seal to mitigate the risk of unauthorized exposure, say attorneys at Redgrave.
-
Series
Judging Figure Skating Makes Me A Better Lawyer
Judging figure skating competitions helps me hone the focus, decisiveness and ability to process complex real-time information I need in court, but more importantly, it makes me reengage with a community and my identity outside of law, which, paradoxically, always brings me back to work feeling restored, says Megan Raymond at Groombridge Wu.
-
Trending At The PTAB: Petitioners' Settled Expectations
Recent Patent Trial and Appeal Board decisions show that the U.S. Patent and Trademark Office's new "settled expectations" factor is no longer the exclusive domain of patent owners and can also provide petitioners with viable pathways to argue against discretionary denial, say attorneys at Finnegan.